Physiomics Announces License Agreement with Eli Lilly
Physiomics announced that it has signed a license agreement with Eli Lilly and Company. Under the terms of the agreement, Physiomics will license to Lilly a customised version of its “ModelPlayer” for in silico simulations of unspecified anticancer drugs and Lilly will have the option to purchase additional licenses.
‘We are delighted with the continued interest shown by Lilly in Physiomics’ technology. We hope that the capability for Lilly scientists to directly use Physiomics’ models will strengthen the quality of the interactions within our ongoing research collaborations. This is also an important commercial and technical milestone for Physiomics as this is the first time that we have out-licensed our technology.’
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

New gel to promote bone growth on implants

Phagocytes from the culture dish for cancer therapy - "Our induced phagocytes have the potential to destroy cancer cells in therapeutic applications by devouring them"
Basilea's Toctino (alitretinoin) receives marketing authorization in Finland
Researchers uncover genetic link to cattle diseases
Amyloid formation may link Alzheimer disease and type 2 diabetes

How bacteria can be "tamed" for sustainable plastics production - Research team at Giessen University develops new system for tailored control of gene expression
Pesticides keep fungus poisons out of the food chain - New study confirms contribution of Azole class fungicides to food safety and productivity

How does Parkinson's disease develop? - Study raises doubts on a previous theory of Parkinson’s disease
